Advocacy group alleges Sanofi-Shire conspiracy

Share this article:

Shire's March 2012 decision to walk away from the chance to market its drug Replagal in the US and put it in direct competition with Sanofi's Fabrazyme is now being pilloried as a possible conspiracy between the two drugmakers, as opposed to Shire's disinterest in investing in more research for an FDA approval. Both drugs treat the rare condition Fabry disease, in which a specific type of fat accumulates in the cells and can cause kidney and heart disease, among other problems.

The Wall Street Journal reports that a consumer advocacy group alleges that Shire decided to give Sanofi the US market if it would be allowed to sell its drug in Europe, and is asking the Federal Trade Commission to give the situation a once-over.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters